The main purpose of this study is to assess the protective effectiveness of six new vaccines against malaria in healthy volunteers. The vaccines are derived from two different types of virus which contain genetic information (DNA) from the malaria parasite. This genetic material produces a parasite component named MSP1, AMA1 or ME-TRAP. Both viruses are changed so that they are unable to multiply within the body. The first vaccine virus is a weakened version of a common cold virus which usually infects chimpanzees and is called an adenovirus. The vaccines made from this virus are called AdCh63 MSP1, AdCh63 AMA1 & AdCH63 ME-TRAP. The other virus is Modified Vaccinia Ankara Virus (MVA) which is a safer form of the virus previously widely used for smallpox vaccination. The vaccines made from this virus are called MVA MSP1, MVA AMA1 & MVA ME-TRAP. Volunteers will receive varying vaccine regimens and will then be infected with malaria to see how effective the vaccines are at pre